UNSPSC 51342003: Pleconaril

This classification denotes an anti-infective agent with the molecular formula C18H18F3N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9H4570Q89D, chemically known as 1,2,4-oxadiazole, 3-(3,5-dimethyl-4-(3-(3-methyl-5-isoxazolyl)propoxy)phenyl)-5-(trifluoromethyl)- but generally known as pleconaril, which bears US NIH Compound Identifier 1684. European Medicines Agency schedules Pleconaril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09957MIG.

UNSPSC 51342003 Pleconaril is a Commodity code under which state and local governments procure pharmaceutical products and emergency medical supplies for public health, emergency response, and community health initiatives. Recent solicitations show purchasing activity spanning naloxone and drug deactivation systems for community health programs, generic pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and medical and first aid supplies for emergency responders. The issuing bodies include county health departments, state health and human services agencies, municipalities, and multistate cooperative purchasing alliances, reflecting a mix of direct procurement by local and state health authorities and coordinated purchasing through cooperative vehicles that aggregate demand across multiple jurisdictions.

Geographic activity centers on Florida, Texas, and Minnesota, with multistate reach through cooperative purchasing arrangements such as MMCAP. Representative recent opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB60459723LAS, due July 26, 2023), the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000.00 (26P00145, due March 13, 2026, sheltered for certified Small Local Business Enterprises with a 5 percent bid discount), the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescriptions (HHS0017013, response deadline April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, proposals due March 26, 2026). The Tampa procurement carries a small-business set-aside and discount; the MMCAP RFP does not specify set-aside designations and requires compliance with cGMP and DSCSA standards, along with a 3 percent administrative fee.